{"schema_version":"secwatch.filing_event.v1","accession":"0001906324-23-000008","form_type":"8-K","ticker":"QDEL","cik":"0001906324","company_name":"QuidelOrtho Corp","filed_at":"2023-02-15T23:59:59+00:00","discovered_at":"2026-05-14T18:03:47.425570+00:00","generated_at":"2026-06-19T12:15:20.578329+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"QuidelOrtho reports Q4 2022 revenue $866.5M, GAAP EPS $0.45; supplemental adjusted EPS $1.76 down 66% YoY","bullets":["Q4 GAAP EPS $0.45 vs $6.85 prior year; supplemental adjusted EPS $1.76, down 66% YoY.","Revenue $866.5M, up 36% as reported; supplemental combined revenue down 23% constant currency ex-COVID.","Full year 2022 GAAP EPS $9.56; supplemental adjusted EPS $13.80, up 1%.","Ex-COVID growth driven by Point of Care and Molecular Diagnostics; Labs weak due to China lockdowns and supply chain.","Integration cost synergies ahead of plan; 2023 guidance to be provided on conference call."],"urls":{"canonical":"https://secwatch.observer/filing/0001906324-23-000008","json":"https://secwatch.observer/filing/0001906324-23-000008.json","markdown":"https://secwatch.observer/filing/0001906324-23-000008.md","text":"https://secwatch.observer/filing/0001906324-23-000008.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1906324/000190632423000008/0001906324-23-000008-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1906324/000190632423000008/qdel-20230215.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-19T12:15:20.578329+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"055ef1cb021db730e4fe9088464efdbc72376add","claim":"QuidelOrtho Corp reported fourth quarter ended January 1, 2023 results: revenue $866.5 million, EPS $0.45.","evidence_excerpt":"language in such filing. --- EX-99.1 (EX-99.1) --- QuidelOrtho Reports Fourth Quarter and Full Year 2022 Financial Results Highlights • Fourth quarter revenue of $866.5 million increased by 36% as reported and 19% on a supplemental combined basis, excluding COVID-19 revenue • Full year revenue of $3.27 billion increased by 92% as reported; Supplemental","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1906324/000190632423000008/0001906324-23-000008-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"fourth quarter ended January 1, 2023"},{"label":"Revenue","value":"$866.5 million"},{"label":"EPS","value":"$0.45"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"0c2149104c4a4dac7163b64e7dad19b23ee29e93","claim":"QuidelOrtho Corp reported full year ended January 1, 2023 results: revenue $3.27 billion, EPS $9.56.","evidence_excerpt":"Full year revenue of $3.27 billion increased by 92% as reported","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1906324/000190632423000008/0001906324-23-000008-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"full year ended January 1, 2023"},{"label":"Revenue","value":"$3.27 billion"},{"label":"EPS","value":"$9.56"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}